findmyKOL

Savitha Subramanian

Basic profile

Gates Foundation

ORCIDNPI
RegionSeattle, WA · WestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Savitha Subramanian is an Endocrinology/Metabolic physician affiliated with Gates Foundation. OpenAlex indexes 88 publications with 3,304 citations (h-index 30).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
88publications

Distinct works indexed by OpenAlex, matched via ORCID.

3,304citations

Total citations across indexed works.

30h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

5 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    51.2%
    Insulin Analog23.8%
    Lantus Solostar36%Novolog Flexpen21%Humalog Kwikpen U-10018%Novolog7%Basaglar Kwikpen U-1006%Insulin Lispro Kwikpen U-1006%Lantus6%
    Part D<11 patients
    Biguanide (metformin)10.3%
    Metformin Hcl65%Metformin Hcl Er36%
    Part D18 patients

    + 3 more classes in this area

  • Cardiovascular

    43.8%
    PCSK9 Inhibitor16.4%
    Repatha Sureclick61%Praluent Pen39%
    Part D21 patients
    Statin14.1%
    Rosuvastatin Calcium56%Atorvastatin Calcium45%
    Part D25 patients

    + 5 more classes in this area

  • Hormonal (systemic)

    5.1%
    l-Thyroxine5.1%
    Levothyroxine Sodium100%
    Part D13 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”